^
Association details:
| Biomarker: | BRAF mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | pimasertib (AS703026) (MEK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Published date:
11/19/2020
Excerpt:
Results from this phase I study indicate that pimasertib has clinical activity in patients with locally advanced/metastatic melanoma, particularly BRAF- and NRAS-mutated tumors...
DOI:
10.1007/s11523-020-00767-1
Trial ID:
